Screener / SEC EDGAR /CIK 0001082554 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

UNITED THERAPEUTICS Corp UTHR

Compare with peers Embed
FY2025 at a glance

Sales up 10.6%, free cash flow down to $1.0B

XBRL, from each 10-K
RevenueStatements
$3.2B from $2.9B in FY2024
FY2016FY2025
Net incomeStatements
$1.3B from $1.2B in FY2024
FY2016FY2025
Free cash flowStatements
$1.0B from $1.1B in FY2024
FY2016FY2025
EPS (diluted)Statements
$27.86 from $24.64 in FY2024
FY2016FY2025
Operating marginStatements
46.9% from 47.9% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (43)
EPS (ttm)
26.49
Sales (ttm)
3.2B
Net income (ttm)
1.2B
Sales growth
+10.6%
EPS growth
+13.1%
Sales Q/Q
+4.1%
Free cash flow
867.2M
Gross margin
86.3%
Oper. margin
41.4%
Net margin
38.6%
FCF margin
27.2%
R&D / sales
17.3%
Dividend
-
Debt/Eq
-
Curr. ratio
4.61
Cash
1.2B
Op. cash flow (ttm)
1.4B
EBITDA
1.6B
EBITDA margin
49.6%
Quick ratio
4.32
Interest cover
76.54
ROIC
18.5%
FCF after stock pay
893.0M
Goodwill / assets
0.4%
Oper. margin low 5y
33.0%
Tax rate
22.1%
Stock pay / sales
4.6%
Shares out.
42.6M
Shares Y/Y
-1.2%
Book / share
147.36
Cash / share
27.92
Sales / share
74.84
Asset turnover
0.45
Inventory turns
2.10
Days sales out.
40
Sales 3Y CAGR
+18.0%
Sales 5Y CAGR
+16.5%
EPS 3Y CAGR
+22.9%
EPS 5Y CAGR
+19.3%
Employees
1,400
Sales / employee
2.3M

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 3.2B +7.9% a year Net income 1.3B +7.2% a year
FY2016 revenue 1.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001047469-19-000724 FY2016 net income 713.7M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001047469-19-000724 1.6B FY2016 FY2017 revenue 1.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104659-20-025009 FY2017 net income 417.9M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001104659-20-025009 1.7B FY2017 FY2018 revenue 1.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001082554-21-000008 FY2018 net income 589.2M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001082554-21-000008 1.6B FY2018 FY2019 revenue 1.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001082554-22-000004 FY2019 net income -104.5M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001082554-22-000004 1.4B FY2019 FY2020 revenue 1.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001082554-23-000005 FY2020 net income 514.8M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001082554-23-000005 1.5B FY2020 FY2021 revenue 1.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001082554-24-000005 FY2021 net income 475.8M · NetIncomeLoss, 0001082554-24-000005 1.7B FY2021 FY2022 revenue 1.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001082554-25-000005 FY2022 net income 727.3M · NetIncomeLoss, 0001082554-25-000005 1.9B FY2022 FY2023 revenue 2.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001082554-26-000006 FY2023 net income 984.8M · NetIncomeLoss, 0001082554-26-000006 2.3B FY2023 FY2024 revenue 2.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001082554-26-000006 FY2024 net income 1.2B · NetIncomeLoss, 0001082554-26-000006 2.9B FY2024 FY2025 revenue 3.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001082554-26-000006 FY2025 net income 1.3B · NetIncomeLoss, 0001082554-26-000006 3.2B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +8.2% a year FY2015 $12.72 to FY2025 $27.86, 10 years
Book value per share +16.9% a year FY2015 $31.03 to FY2025 $148.15, 10 years
Free cash flow per share +12.8% a year FY2015 $6.50 to FY2025 $21.73, 10 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $27.86$148.15$21.73
Dec 31, 2024 $24.64$132.87$22.28
Dec 31, 2023 $19.81$120.42$15.04
Dec 31, 2022 $15.00$98.90$13.68
Dec 31, 2021 $10.06$83.70$10.09
Dec 31, 2020 $11.54$76.13$15.61
Dec 31, 2019 -$2.39$63.48-$6.63
Dec 31, 2018 $13.39$63.38$13.50
Dec 31, 2017 $9.31$46.81$8.64
Dec 31, 2016 $15.25$39.56$12.94
Dec 31, 2015 $12.72$31.03$6.50

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $3.7B
  • − All liabilities $783.8M
  • = Net current asset value $2.9B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $7.1B
  • − Goodwill $32.3M
  • = Tangible book value $7.1B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

UTHR against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+10.6%77th of 155 · median +10.5%
Net margin
-4.1%15.3%
38.6%4th of 154 · median 6.8%
Return on equity
-5.2%18.5%
19.6%31st of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
27.2%14th of 145 · median 10.0%
UTHR and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
UTHR UNITED THERAPEUTICS Corp$3.2B +10.6%86.3%38.6%19.6%27.2%-
WST West Pharmaceutical Services$3.4B +6.3%37.6%18.8%21.5%13.3%0.07
SGRY Surgery Partners, Inc.$3.4B +6.2%--2.6%-5.2%6.0%1.84
AMRX Amneal Pharmaceuticals, Inc.$3.2B +8.0%40.2%4.2%25.1%2.8%5.53
PODD Insulet Corporation$3.2B +30.7%71.9%13.4%27.1%8.2%0.61
GMED Globus Medical Inc$3.1B +16.7%69.1%17.8%11.6%24.4%-
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by region

From $1.7B of sales to $475.8M of profit FY2021

  • United States $1.6B
  • Rest-of-World $121.3M
Revenue to Gross profit: $1.6BRevenue to Cost of revenue: $122.5MGross profit to Operating profit: $555.9MGross profit to Operating expenses: $1.0BOperating profit to Net profit: $437.8MOperating profit to Tax: $118.1MOther income to Net profit: $38.0MOperating expenses to R&D: $540.1MOperating expenses to SG&A: $467.0M Revenue: $1.7B REVENUE $1.7B +14% Y/Y Gross profit: $1.6B · 93% margin GROSS PROFIT $1.6B 93% margin · +14% Y/Y Cost of revenue: $122.5M · 7% of revenue COST OF REVENUE $122.5M 7% of revenue Operating profit: $555.9M · 33% margin OPERATING PROFIT $555.9M 33% margin · −6% Y/Y Other income: $38.0M · 2% of revenue OTHER INCOME $38.0M 2% of revenue Operating expenses: $1.0B · 60% of revenue OPERATING EXPENSES $1.0B 60% of revenue Net profit: $475.8M · 28% margin NET PROFIT $475.8M 28% margin · −8% Y/Y Tax: $118.1M · 7% of revenue TAX $118.1M 7% of revenue R&D: $540.1M · 32% of revenue R&D $540.1M 32% of revenue SG&A: $467.0M · 28% of revenue SG&A $467.0M 28% of revenue

From $1.9B of sales to $727.3M of profit FY2022

  • United States $1.8B
  • Rest-of-World $122.2M
Revenue to Gross profit: $1.8BRevenue to Cost of revenue: $151.6MGross profit to Operating profit: $979.7MGross profit to Operating expenses: $805.0MOperating profit to Net profit: $727.3MOperating profit to Tax & other: $252.4MOperating expenses to R&D: $322.9MOperating expenses to SG&A: $482.1M Revenue: $1.9B REVENUE $1.9B +15% Y/Y Gross profit: $1.8B · 92% margin GROSS PROFIT $1.8B 92% margin · +14% Y/Y Cost of revenue: $151.6M · 8% of revenue COST OF REVENUE $151.6M 8% of revenue Operating profit: $979.7M · 51% margin OPERATING PROFIT $979.7M 51% margin · +76% Y/Y Operating expenses: $805.0M · 42% of revenue OPERATING EXPENSES $805.0M 42% of revenue Net profit: $727.3M · 38% margin NET PROFIT $727.3M 38% margin · +53% Y/Y Tax & other: $252.4M · 13% of revenue TAX & OTHER $252.4M 13% of revenue R&D: $322.9M · 17% of revenue R&D $322.9M 17% of revenue SG&A: $482.1M · 25% of revenue SG&A $482.1M 25% of revenue

From $2.3B of sales to $984.8M of profit FY2023

  • United States $2.2B
  • Rest-of-World $125.3M
Revenue to Gross profit: $2.1BRevenue to Cost of revenue: $257.5MGross profit to Operating profit: $1.2BGross profit to Operating expenses: $885.1MOperating profit to Net profit: $895.4MOperating profit to Tax: $289.5MOther income to Net profit: $89.4MOperating expenses to R&D: $408.0MOperating expenses to SG&A: $477.1M Revenue: $2.3B REVENUE $2.3B +20% Y/Y Gross profit: $2.1B · 89% margin GROSS PROFIT $2.1B 89% margin · +16% Y/Y Cost of revenue: $257.5M · 11% of revenue COST OF REVENUE $257.5M 11% of revenue Operating profit: $1.2B · 51% margin OPERATING PROFIT $1.2B 51% margin · +21% Y/Y Other income: $89.4M · 4% of revenue OTHER INCOME $89.4M 4% of revenue Operating expenses: $885.1M · 38% of revenue OPERATING EXPENSES $885.1M 38% of revenue Net profit: $984.8M · 42% margin NET PROFIT $984.8M 42% margin · +35% Y/Y Tax: $289.5M · 12% of revenue TAX $289.5M 12% of revenue R&D: $408.0M · 18% of revenue R&D $408.0M 18% of revenue SG&A: $477.1M · 20% of revenue SG&A $477.1M 20% of revenue

From $2.9B of sales to $1.2B of profit FY2024

  • United States $2.7B
  • Rest-of-World $137.7M
Revenue to Gross profit: $2.6BRevenue to Cost of revenue: $309.7MGross profit to Operating profit: $1.4BGross profit to Operating expenses: $1.2BOperating profit to Net profit: $1.0BOperating profit to Tax: $343.9MOther income to Net profit: $162.0MOperating expenses to R&D: $481.0MOperating expenses to SG&A: $709.7M Revenue: $2.9B REVENUE $2.9B +24% Y/Y Gross profit: $2.6B · 89% margin GROSS PROFIT $2.6B 89% margin · +24% Y/Y Cost of revenue: $309.7M · 11% of revenue COST OF REVENUE $309.7M 11% of revenue Operating profit: $1.4B · 48% margin OPERATING PROFIT $1.4B 48% margin · +16% Y/Y Other income: $162.0M · 6% of revenue OTHER INCOME $162.0M 6% of revenue Operating expenses: $1.2B · 41% of revenue OPERATING EXPENSES $1.2B 41% of revenue Net profit: $1.2B · 42% margin NET PROFIT $1.2B 42% margin · +21% Y/Y Tax: $343.9M · 12% of revenue TAX $343.9M 12% of revenue R&D: $481.0M · 17% of revenue R&D $481.0M 17% of revenue SG&A: $709.7M · 25% of revenue SG&A $709.7M 25% of revenue

From $3.2B of sales to $1.3B of profit FY2025

  • United States $3.0B
  • Rest-of-World $145.7M
Revenue to Gross profit: $2.8BRevenue to Cost of revenue: $384.4MGross profit to Operating profit: $1.5BGross profit to Operating expenses: $1.3BOperating profit to Net profit: $1.1BOperating profit to Tax: $379.2MOther income to Net profit: $221.4MOperating expenses to R&D: $550.0MOperating expenses to SG&A: $755.8M Revenue: $3.2B REVENUE $3.2B +11% Y/Y Gross profit: $2.8B · 88% margin GROSS PROFIT $2.8B 88% margin · +9% Y/Y Cost of revenue: $384.4M · 12% of revenue COST OF REVENUE $384.4M 12% of revenue Operating profit: $1.5B · 47% margin OPERATING PROFIT $1.5B 47% margin · +8% Y/Y Other income: $221.4M · 7% of revenue OTHER INCOME $221.4M 7% of revenue Operating expenses: $1.3B · 41% of revenue OPERATING EXPENSES $1.3B 41% of revenue Net profit: $1.3B · 42% margin NET PROFIT $1.3B 42% margin · +12% Y/Y Tax: $379.2M · 12% of revenue TAX $379.2M 12% of revenue R&D: $550.0M · 17% of revenue R&D $550.0M 17% of revenue SG&A: $755.8M · 24% of revenue SG&A $755.8M 24% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 18.8% FY2020: 15.2% net income ÷ equity
Net margin 41.9% FY2020: 34.7% profit per $ of sales: 1.3B ÷ 3.2B
Asset turnover 0.40× FY2020: 0.32× sales per $ of assets: 3.2B ÷ 7.9B
Leverage 1.11× FY2020: 1.36× assets per $ of equity: 7.9B ÷ 7.1B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    38.6% vs 6.8%
  • Gross margin down over 5 years
    92.7% → 87.9%
  • Return on equity above 15%
    19.6%
  • A profit in 9 of 10 years
Net margin, FY2016 to FY2025: 44.6% to 41.9%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 76.5× interest expense
  • Current assets cover current liabilities
    Current ratio 4.61

Cash and shareholders

  • Free cash flow positive in 9 of 10 years
    $1.0B last year
  • Share count up over 5 years
    +7.4%
  • Cash from operations above net income
    $1.6B vs $1.3B
Free cash flow, FY2016 to FY2025: 605.6M to 1.0B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

UTHR's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue3.2B
FY2016: 1.6BFY2017: 1.7BFY2018: 1.6BFY2019: 1.4BFY2020: 1.5BFY2021: 1.7BFY2022: 1.9BFY2023: 2.3BFY2024: 2.9BFY2025: 3.2B FY2017FY2019FY2021FY2023FY2025
Net income1.3B
FY2016: 713.7MFY2017: 417.9MFY2018: 589.2MFY2019: -104.5MFY2020: 514.8MFY2021: 475.8MFY2022: 727.3MFY2023: 984.8MFY2024: 1.2BFY2025: 1.3B FY2017FY2019FY2021FY2023FY2025
Free cash flow1.0B
FY2016: 605.6MFY2017: 387.9MFY2018: 594.0MFY2019: -290.3MFY2020: 696.4MFY2021: 477.4MFY2022: 663.7MFY2023: 747.6MFY2024: 1.1BFY2025: 1.0B FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay893.0M
FY2016: 593.5MFY2017: 314.4MFY2018: 620.4MFY2019: -335.7MFY2020: 532.6MFY2021: 338.9MFY2022: 556.9MFY2023: 708.5MFY2024: 936.6MFY2025: 893.0M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)27.86
FY2016: 15.25FY2017: 9.31FY2018: 13.39FY2019: -2.39FY2020: 11.54FY2021: 10.06FY2022: 15.00FY2023: 19.81FY2024: 24.64FY2025: 27.86 FY2017FY2019FY2021FY2023FY2025
Diluted shares47.9M
FY2016: 46.8MFY2017: 44.9MFY2018: 44.0MFY2019: 43.8MFY2020: 44.6MFY2021: 47.3MFY2022: 48.5MFY2023: 49.7MFY2024: 48.5MFY2025: 47.9M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Total Tyvaso 1.9B59.0% +15.9%
Tyvaso DPI 1.3B40.6% +25.0%
Nebulized Tyvaso 585.7M18.4% -0.2%
Remodulin 526.8M16.6% -2.1%
Orenitram 496.9M15.6% +14.4%
Unituxin 226.8M7.1% -5.0%
Adcirca 30.0M0.9% +26.1%

10-K 0001082554-26-000006, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 3.0B95.4% +10.9%
Rest-of-World 145.7M4.6% +5.8%

10-K 0001082554-26-000006, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1.6B1.7B1.6B1.4B1.5B1.7B1.9B2.3B2.9B3.2B
Cost of revenue72.7M105.7M198.7M117.6M108.1M122.5M151.6M257.5M309.7M384.4M
Gross profit---1.3B1.4B1.6B1.8B2.1B2.6B2.8B
R&D147.6M264.6M357.9M1.2B357.7M540.1M322.9M408.0M481.0M550.0M
SG&A316.8M330.1M265.8M--467.0M482.1M477.1M709.7M755.8M
Operating income1.1B814.9M805.4M-187.6M593.6M555.9M979.7M1.2B1.4B1.5B
Interest expense3.9M9.0M13.9M44.2M23.5M18.6M32.4M59.3M42.9M19.5M
Pretax income1.1B769.5M758.9M-165.0M638.9M593.9M950.6M1.3B1.5B1.7B
Income tax346.5M351.6M169.7M-60.5M124.1M118.1M223.3M289.5M343.9M379.2M
Net income713.7M417.9M589.2M-104.5M514.8M475.8M727.3M984.8M1.2B1.3B
EPS (diluted)15.259.3113.39-2.3911.5410.0615.0019.8124.6427.86
Diluted shares46.8M44.9M44.0M43.8M44.6M47.3M48.5M49.7M48.5M47.9M
Depreciation & amortization31.6M31.0M35.9M45.9M49.9M49.9M51.3M53.2M72.5M85.6M
EBITDA1.1B845.9M841.3M-141.7M643.5M605.8M1.0B1.2B1.4B1.6B
Gross margin---91.9%92.7%92.7%92.2%88.9%89.2%87.9%
Operating margin66.4%47.2%49.5%-12.9%40.0%33.0%50.6%50.9%47.9%46.9%
Net margin44.6%24.2%36.2%-7.2%34.7%28.2%37.6%42.3%41.5%41.9%
Revenue growth+9.1%+7.9%-5.7%-11.0%+2.4%+13.6%+14.9%+20.2%+23.6%+10.6%
EPS growth+19.9%-39.0%+43.8%to a loss--12.8%+49.1%+32.1%+24.4%+13.1%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow643.6M474.2M778.4M-206.6M755.7M598.2M802.5M978.0M1.3B1.6B
Capital spending38.0M86.3M184.4M83.7M59.3M120.8M138.8M230.4M246.5M520.5M
Free cash flow605.6M387.9M594.0M-290.3M696.4M477.4M663.7M747.6M1.1B1.0B
Stock-based pay (added back)12.1M73.5M-26.4M45.4M163.8M138.5M106.8M39.1M144.0M147.7M
Free cash flow after stock pay593.5M314.4M620.4M-335.7M532.6M338.9M556.9M708.5M936.6M893.0M
Buybacks500.0M250.0M----001.0B1.0B
Acquisitions5.2M-124.1M000089.2M00
Investing cash flow48.3M-835.6M-820.6M-335.4M-738.5M-486.9M-811.5M-719.6M417.2M-551.3M
Financing cash flow-497.7M43.3M6.3M611.2M-16.9M44.8M75.4M-11.9M-1.3B-1.1B

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)12.1M73.5M-26.4M45.4M163.8M138.5M106.8M39.1M144.0M147.7M
Stock-based pay / revenue0.8%4.3%-1.6%3.1%11.0%8.2%5.5%1.7%5.0%4.6%
Operating lease cost-----3.6M4.8M5.7M7.6M8.9M
Right-of-use assets--8.2M4.8M------
Operating lease liabilities--8.2M4.8M------

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/UTHR/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.